281 related articles for article (PubMed ID: 17927474)
1. Expanding role of lipid II as a target for lantibiotics.
Martin NI; Breukink E
Future Microbiol; 2007 Oct; 2(5):513-25. PubMed ID: 17927474
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial mechanism of lantibiotics.
Islam MR; Nagao J; Zendo T; Sonomoto K
Biochem Soc Trans; 2012 Dec; 40(6):1528-33. PubMed ID: 23176511
[TBL] [Abstract][Full Text] [Related]
3. Lipid II as a target for antibiotics.
Breukink E; de Kruijff B
Nat Rev Drug Discov; 2006 Apr; 5(4):321-32. PubMed ID: 16531990
[TBL] [Abstract][Full Text] [Related]
4. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.
Hasper HE; Kramer NE; Smith JL; Hillman JD; Zachariah C; Kuipers OP; de Kruijff B; Breukink E
Science; 2006 Sep; 313(5793):1636-7. PubMed ID: 16973881
[TBL] [Abstract][Full Text] [Related]
5. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.
de Kruijff B; van Dam V; Breukink E
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(3-5):117-21. PubMed ID: 19008088
[TBL] [Abstract][Full Text] [Related]
6. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.
Arnusch CJ; Bonvin AM; Verel AM; Jansen WT; Liskamp RM; de Kruijff B; Pieters RJ; Breukink E
Biochemistry; 2008 Dec; 47(48):12661-3. PubMed ID: 18989934
[TBL] [Abstract][Full Text] [Related]
7. Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.
Müller A; Ulm H; Reder-Christ K; Sahl HG; Schneider T
Microb Drug Resist; 2012 Jun; 18(3):261-70. PubMed ID: 22432708
[TBL] [Abstract][Full Text] [Related]
8. A lesson in efficient killing from two-component lantibiotics.
Breukink E
Mol Microbiol; 2006 Jul; 61(2):271-3. PubMed ID: 16771845
[TBL] [Abstract][Full Text] [Related]
9. Lipid II and other bactoprenol-bound cell wall precursors as drug targets.
Schneider T; Sahl HG
Curr Opin Investig Drugs; 2010 Feb; 11(2):157-64. PubMed ID: 20112165
[TBL] [Abstract][Full Text] [Related]
10. Hit 'em where it hurts: The growing and structurally diverse family of peptides that target lipid-II.
Oppedijk SF; Martin NI; Breukink E
Biochim Biophys Acta; 2016 May; 1858(5):947-57. PubMed ID: 26523408
[TBL] [Abstract][Full Text] [Related]
11. Docking on Lipid II-A Widespread Mechanism for Potent Bactericidal Activities of Antibiotic Peptides.
Grein F; Schneider T; Sahl HG
J Mol Biol; 2019 Aug; 431(18):3520-3530. PubMed ID: 31100388
[TBL] [Abstract][Full Text] [Related]
12. Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic.
Islam MR; Nishie M; Nagao J; Zendo T; Keller S; Nakayama J; Kohda D; Sahl HG; Sonomoto K
J Am Chem Soc; 2012 Feb; 134(8):3687-90. PubMed ID: 22329487
[TBL] [Abstract][Full Text] [Related]
13. The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.
Wiedemann I; Böttiger T; Bonelli RR; Wiese A; Hagge SO; Gutsmann T; Seydel U; Deegan L; Hill C; Ross P; Sahl HG
Mol Microbiol; 2006 Jul; 61(2):285-96. PubMed ID: 16771847
[TBL] [Abstract][Full Text] [Related]
14. Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.
Wiedemann I; Böttiger T; Bonelli RR; Schneider T; Sahl HG; Martínez B
Appl Environ Microbiol; 2006 Apr; 72(4):2809-14. PubMed ID: 16597986
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics.
Leimkuhler C; Chen L; Barrett D; Panzone G; Sun B; Falcone B; Oberthür M; Donadio S; Walker S; Kahne D
J Am Chem Soc; 2005 Mar; 127(10):3250-1. PubMed ID: 15755121
[TBL] [Abstract][Full Text] [Related]
16. Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.
Böttiger T; Schneider T; Martínez B; Sahl HG; Wiedemann I
Appl Environ Microbiol; 2009 Jul; 75(13):4427-34. PubMed ID: 19429551
[TBL] [Abstract][Full Text] [Related]
17. Getting closer to the real bacterial cell wall target: biomolecular interactions of water-soluble lipid II with glycopeptide antibiotics.
Vollmerhaus PJ; Breukink E; Heck AJ
Chemistry; 2003 Apr; 9(7):1556-65. PubMed ID: 12658654
[TBL] [Abstract][Full Text] [Related]
18. Targeting extracellular pyrophosphates underpins the high selectivity of nisin.
Bonev BB; Breukink E; Swiezewska E; De Kruijff B; Watts A
FASEB J; 2004 Dec; 18(15):1862-9. PubMed ID: 15576489
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria.
Héchard Y; Sahl HG
Biochimie; 2002; 84(5-6):545-57. PubMed ID: 12423799
[TBL] [Abstract][Full Text] [Related]
20. Posttranslationally modified bacteriocins--the lantibiotics.
Guder A; Wiedemann I; Sahl HG
Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
